

DEAV2000/A043 US NP1

PATENT

**REMARKS**

Upon entry of the foregoing amendments, claims 1 to 6 and 8 to 9 will be pending in the above-identified patent application. Claims 1 and 2 have been amended. Claim 7 has been canceled, without prejudice. No new matter has been added.

In view of the foregoing amendments and the remarks that follow, reconsideration and withdrawal of the rejections are requested respectfully.

**Discussion of the Rejection Under 35 U.S.C. § 112, Second Paragraph**

Claims 1 to 9 have been rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter that Applicants regard as the invention. Although Applicants disagree respectfully that claims 1 to 9 are indefinite, Applicants submit that this rejection is moot in view of the foregoing amendments.

**Discussion of the Rejection Under 35 U.S.C. § 112, Second Paragraph**

Claim 7 has been rejected under 35 U.S.C. §112, first paragraph, as allegedly lacking enablement. In particular, it is alleged that the specification does not provide an enabling disclosure for the treatment of "all or any cardiovascular disorders" (Action at 6). Although Applicants disagree respectfully that claim 7 is not enabled by the present disclosure, Applicants have nonetheless canceled claim 7 for the sole purpose of advancing the prosecution of the present patent application. Accordingly, Applicants submit respectfully that this rejection is now moot. Applicants, however, reserve the right to pursue the subject matter of claim 7 in a later-filed continuation application.


**DEAV2000/A043 US NP1****PATENT****Conclusion**

Applicants believe that the foregoing constitutes a complete and full response to the Action of record. Applicants respectfully submit that this application is now in condition for allowance. Accordingly, an indication of allowability and an early Notice of Allowance are respectfully requested.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Dated: July 18, 2005

  
Joseph D. Rossi, Registration No. 47,038  
Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-3410  
Telefax: 908-231-2626  
Docket No. DEAV2000/A043 US NP1